Literature DB >> 22241721

Applying new clinicopathological characteristics to prognostication in advanced thyroid carcinoma.

Maria E Cabanillas1, Steven I Sherman.   

Abstract

In the February 2011 issue of Endocrine-Related Cancer, Deandreis et al. reported that increased FDG uptake was prognostic in patients with metastatic thyroid cancer. Fludeoxyglucose-positron emission tomography (FDG-PET) is routinely used in the staging and follow-up of patients with cancer. This study gives further evidence for the role of FDG-PET scanning in metastatic thyroid cancer, especially to identify patients with aggressive disease requiring systemic therapy.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22241721      PMCID： PMC4039023          DOI： 10.1530/ERC-11-0371

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN： 1351-0088            Impact factor:   5.678


  18 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning.

Authors:  Richard J Robbins; Qiang Wan; Ravinder K Grewal; Roland Reibke; Mithat Gonen; H William Strauss; R Michael Tuttle; William Drucker; Steven M Larson
Journal:  J Clin Endocrinol Metab       Date:  2005-11-22       Impact factor: 5.958

Review 3.  Prognostic factors of clinical interest in poorly differentiated carcinomas of the thyroid.

Authors:  Marco Volante; Gianni P Cavallo; Mauro Papotti
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

4.  Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer.

Authors:  W Wang; S M Larson; M Fazzari; S K Tickoo; K Kolbert; G Sgouros; H Yeung; H Macapinlac; J Rosai; R J Robbins
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

5.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

Authors:  William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

6.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

7.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

8.  ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.

Authors:  Ginesa Garcia-Rostan; Hongyu Zhao; Robert L Camp; Marina Pollan; Agustin Herrero; Javier Pardo; Ran Wu; Maria Luisa Carcangiu; Jose Costa; Giovanni Tallini
Journal:  J Clin Oncol       Date:  2003-09-01       Impact factor: 44.544

9.  The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma.

Authors:  Riccardo Giannini; Clara Ugolini; Cristiana Lupi; Agnese Proietti; Rossella Elisei; Giuliana Salvatore; Piero Berti; Gabriele Materazzi; Paolo Miccoli; Massimo Santoro; Fulvio Basolo
Journal:  J Clin Endocrinol Metab       Date:  2007-05-29       Impact factor: 5.958

10.  Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients.

Authors:  David Hiltzik; Diane L Carlson; R Michael Tuttle; Shaokun Chuai; Nicole Ishill; Ashok Shaha; Jatin P Shah; Buvanesh Singh; Ronald A Ghossein
Journal:  Cancer       Date:  2006-03-15       Impact factor: 6.860
View more
  1 in total

1.  Efficacy of sorafenib and impact on cardiac function in patients with thyroid cancer: a retrospective analysis.

Authors:  L Mortara; G Pera; E Monti; S Morbelli; F Minuto; G Sambuceti; M Giusti
Journal:  J Endocrinol Invest       Date:  2014-10-05       Impact factor: 4.256
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.